(firstQuint)HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma.

 The study is closed and all subjects have completed treatment.

 The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma.

 The primary efficacy will be evaluated by time to relapse.

.

 HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma@highlight

The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.

